BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.nebraska.edu

Clinical Trials

Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: fluorouracil
Drug: gemcitabine hydrochloride
Drug: leucovorin calcium
Drug: oxaliplatin
Procedure: adjuvant therapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Radiation: radiation therapy

First Posted Date: 2004-08-05

Last Posted Date: 2023-09-29

Lead Sponsor: University of Nebraska

Target Recruit Count: 29

Registration Number: NCT00089024

Locations: 🇺🇸
Eppley Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, United States

Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Neutropenia
Lymphoma

Interventions: Biological: filgrastim
Biological: pegfilgrastim
Drug: cisplatin
Drug: cytarabine
Drug: etoposide
Drug: methylprednisolone

First Posted Date: 2004-06-25

Last Posted Date: 2023-12-27

Lead Sponsor: University of Nebraska

Target Recruit Count: 60

Registration Number: NCT00004192

Locations: 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-06-25

Last Posted Date: 2023-09-07

Lead Sponsor: University of Nebraska

Registration Number: NCT00004197

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2004-05-25

Last Posted Date: 2023-12-27

Lead Sponsor: University of Nebraska

Registration Number: NCT00004112

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-05-21

Last Posted Date: 2023-12-27

Lead Sponsor: University of Nebraska

Registration Number: NCT00004198

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: autologous dendritic cell-adenovirus p53 vaccine

First Posted Date: 2004-05-19

Last Posted Date: 2023-09-22

Lead Sponsor: University of Nebraska

Target Recruit Count: 24

Registration Number: NCT00082641

Locations: 🇺🇸
Eppley Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, United States

Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: autologous bone marrow transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-04-08

Last Posted Date: 2023-10-06

Lead Sponsor: University of Nebraska

Target Recruit Count: 68

Registration Number: NCT00080886

Locations: 🇺🇸
University of Nebraska Medical Center, Eppley Cancer Center, Omaha, Nebraska, United States

Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2004-02-12

Last Posted Date: 2023-09-01

Lead Sponsor: University of Nebraska

Target Recruit Count: 44

Registration Number: NCT00007852

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 3

Terminated

Conditions: Lymphoma

First Posted Date: 2003-12-16

Last Posted Date: 2018-01-17

Lead Sponsor: University of Nebraska

Target Recruit Count: 31

Registration Number: NCT00004874

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-09-18

Last Posted Date: 2013-07-10

Lead Sponsor: University of Nebraska

Target Recruit Count: 30

Registration Number: NCT00002638

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy